Month: April 2025
Tuesday assorted links
The Free Press
This is from the Free Press website, written by me, so I will not indent:
The Free Press is where I have decided to make my new intellectual home.
In a rapidly changing world, I feel The Free Press is the correct base for me, and it has the audience I wish to reach.
First, The Free Press is a start-up.
And because The Free Press is a start-up, it can fail. Many people do not like that fact about start-ups, because they do not want to be part of a possible failure. It means disruption, and also the paycheck stops coming. But I enjoy the risk appetite. It is precisely because it can fail that the people here will work harder, and likely smarter, than the competition.
That it is a start-up is not only true in fact, but you sense it the moment you walk into the newsroom, which I did for the first time recently. The place has overwhelming vibes and energy, and you can feel those in each and every person on the floor.
I think we are entering an era where “floor energy” will matter more than before. It will motivate, define, and lift some institutions well above the others.
A lot of The Free Press is charisma- and personality-based. Much of that comes from Bari Weiss, but there are numerous strong personalities on the roster, covering a wide range of topics, and I know they are keen to bring on even more. I expect the importance of charisma- and personality-based content to rise sharply in the near future.
I don’t know if The Free Press knows this yet, because they tend to be old-school, but pretty soon quality AI programs will write better columns than most of what is considered acceptable at top mainstream media outlets. Of course those columns will not be by human beings, and so those writings will not be able to contextualize themselves within the framework of what a particular individual thinks or feels. That kind of context will be all-important, as impersonal content, based on broadly available public information, will be outcompeted by the machines.
I believe The Free Press intellectual and business model is well-positioned to handle this transition. At The Free Press, and for Free Press readers, the individual writer and personality truly matters, and will continue to matter.
I have written for about 10 years for The New York Times and about eight years for Bloomberg Opinion. Both were wonderful experiences, and I worked with great people and benefited enormously from those relationships. But I am now oh, so very excited about this next step.
Stay tuned for my first official column this Thursday. Click here to make sure you get my work delivered directly to your inbox.
Last but not least: Join Bari and me for a livestream Q+A only for paid members of The Free Press. Come to our website on Thursday, April 3 at 4:30 p.m. ET to watch the conversation.
AI Discovers New Uses for Old Drugs
The NYTimes has an excellent piece by Kate Morgan on AI discovering new uses for old drugs:
A little over a year ago, Joseph Coates was told there was only one thing left to decide. Did he want to die at home, or in the hospital?
Coates, then 37 and living in Renton, Wash., was barely conscious. For months, he had been battling a rare blood disorder called POEMS syndrome, which had left him with numb hands and feet, an enlarged heart and failing kidneys. Every few days, doctors needed to drain liters of fluid from his abdomen. He became too sick to receive a stem cell transplant — one of the only treatments that could have put him into remission.
“I gave up,” he said. “I just thought the end was inevitable.”
But Coates’s girlfriend, Tara Theobald, wasn’t ready to quit. So she sent an email begging for help to a doctor in Philadelphia named David Fajgenbaum, whom the couple met a year earlier at a rare disease summit.
By the next morning, Dr. Fajgenbaum had replied, suggesting an unconventional combination of chemotherapy, immunotherapy and steroids previously untested as a treatment for Coates’s disorder.
Within a week, Coates was responding to treatment. In four months, he was healthy enough for a stem cell transplant. Today, he’s in remission.
The lifesaving drug regimen wasn’t thought up by the doctor, or any person. It had been spit out by an artificial intelligence model.
AI is excellent at combing through large amounts of data to find surprising connections.
Discovering new uses for old drugs has some big advantages and one disadvantage. A big advantage is that once a drug has been approved for some use it can be prescribed for any use–thus new uses of old drugs do not have to go through the lengthy and arduous FDA approval procedures. In essence, off-label uses have been safety-tested but not FDA efficacy-tested in the new use. I use this fact about off-label prescribing to evaluate the FDA. During COVID, for example, the British Recovery trial, discovered that the common drug, dexamethasone could reduce mortality by up to one-third in hospitalized patients on oxygen support that knowledge was immediately applied, saving millions of lives worldwide:
Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.
New uses for old drugs are typically unpatentable, which helps keep them cheap—but the disadvantage is that this also weakens private incentives to discover them. While FDA trials for these new uses are often unnecessary, making development costs much lower, the lack of strong market protection can still deter investment. The FDA offers some limited exclusivity through programs like 505(b)(2), which grants temporary protection for new clinical trials or safety and efficacy data. These programs are hard to calibrate—balancing cost and reward is difficult—but likely provide some net benefits.
The NIH should continue prioritizing research into unpatentable treatments, as this is where the market is most challenged. More broadly, research on novel mechanisms to support non-patentable innovations is valuable. That said, I’m not overly concerned about under-investment in repurposing old drugs, especially as AI further reduces the cost of discovery.
The Research Behavior of Individual Investors
Browser data from an approximately representative sample of individual investors offers a detailed account of their search for information, including how much time they spend on stock research, which stocks they research, what categories of information they seek, and when they gather information relative to events and trades. The median individual investor spends approximately six minutes on research per trade on traded tickers, mostly just before the trade; the mean spends around half an hour. Individual investors spend the most time reviewing price charts, followed by analyst opinions, and exhibit little interest in traditional risk statistics. Aggregate research interest is highly correlated with stock size, and salient news and earnings announcements draw more attention. Individual investors have different research styles, and those that focus on short-term information are more likely to trade more speculative stocks.
That is from a new NBER working paper by Toomas Laarits and Jeffrey Wurgler.
Living in Freiburg, Germany
After two years at Harvard, I had finished all of my graduate school courses and oral (!) exams. Then I had a compulsion for what I should do next, something that at the time appeared remarkably stupid, although it worked out very well for me.
At some critical points in my life I have made key decisions with regard to place, including Mexico, Haiti, New Zealand, and as I will write about today, Freiburg, Germany. Each of those decisions fundamentally reshaped my life. None of those decisions were motivated by rational reasons, or indeed much by traditional reasons at all. I simply wanted to do particular things, and then set off to do so.
After two years of study, a Harvard PhD student would be expected to apprentice with a top professor, “live in the basement of the Science Center” (where the computers were those days), and in general become part of the system. Somehow none of that fit me. I decided instead to study for a year in Freiburg, Germany, at the university there, mostly to learn German but also to run away from a particular kind of fate that most of my peers were choosing. And so I departed from Cambridge in 1984-85, aided by a strong dollar and a small grant from the Claude R. Lambe Foundation.
Other than an Oxford and London summer trip at age 17, it was my first time abroad. I flew over with Kroszner, and we rented a car to drive around Germany for a few weeks before I would settle in Freiburg.
Our first stop was Mainz, which was not too far from Frankfurt airport. I was stunned by everything I saw, ranging from the supermarkets to the food to how the downtown was organized. These days Mainz is regarded as a fairly dull city, but then, for me, it was fascinating beyond belief. Unlike England, Germany struck me as a peer country to the United States, with a roughly equal living standard and in some ways a superior way of life.
Other stops on our trip included the beautiful Baden-Baden, Stuttgart, Cologne, Hamburg, Bremen, the “Romantic Road” in Bavaria, and of course Berlin. The one day I spent in East Berlin terrified me. Not primarily because of the living standards (which were low), but because the people seemed so fearful and intimidated. I decided that communism was far worse than I had thought. I was relieved to return to West Berlin, which at the time had that Cold War, party town, otherworldly feel. Try watching “Wings of Desire” some day.
Once I settled into Freiurg I was on my own. I refused to hang out with the other American students, and so I learned German pretty quickly. I developed a morning routine of walking to buy the International Herald Tribune, working on my dissertation in the morning on a typewriter, and going into town for lunch and some shopping and errands. Freiburg was the closest I ever have come to living in a proper city, though at the time the population was a mere quarter million or so. Nonetheless one could go “in die Stadt,” an entirely meaningful notion if you know the layout.
I even ended up with a German girlfriend, and from her I learned German all that much better.
Frequently I would feel claustrophobic, and so I would depart for Switzerland, where I would feel even more claustrophobic. Still, I loved those trips, as the sense of perpetual motion was sufficient compensation. Over time I have managed to see every Swiss canton, and I am fond of all of them. For Erleichterung I would visit the Netherlands, or one time Chris Weber came by and we drove to Colmar for Alsatian smoked meats, yum. For Thanksgiving there was an Italy trip to Bergamo and Verona. Later in the spring I went to Venice and Florence.
I had a January lecture tour in Vienna (freezing!), with the Carl Menger Institute, and in May a week-long stint in Graz. My German peers found it literally unbelievable that someone my age had published papers I could present and talk about, in addition to a Wall Street Journal Op-Ed on monetary economics.
I also gave a talk at a jazz club in Vienna, the first (but not last) time I experienced talk-giving as a kind of high class entertainment. I mixed German and English, and told a fair number of jokes, and found I enjoyed that. I am thankful to Albert Zlabinger for arranging that evening.
It was that kind of life. There has never been a year that was more exciting or when I learned more about the world.
Art and painting started making sense to me when I visited the Lenbach Haus in Munich, with Blue Rider works, and the Mondrian museum in The Hague. I retain a special fondness for those artists to this day.
Amsterdam probably was my favorite city, though I now feel it is long since ruined by an excess of tourists. To save money, I would sleep on the houseboats there.
Once I tired of German food, delicious though it may be, I started experimenting on the culinary front, at least as much as I could given my location. That was the time in my life when I started trying everything I could.
It simply stunned me how many things in Germany were better, starting with the bread and orange juice and butter, though hardly ending there.
So every day I learned, learned, learned, and was in pretty constant motion.
By the time I returned to the United States, it was clear I would never be entering on mainstream tracks again.